dr. saad on the safety profile of apalutamide in m0crpc
Published 4 years ago • 142 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
1:47
dr. saad on apalutamide combination for castration-resistant prostate cancer
-
2:32
dr. saad on the spartan trial in m0crpc
-
3:14
fred saad, md, details safety concerns when presenting apalutamide adt to nmcrpc patients
-
1:03
kim n. chi, md, outlines the safety profile of apalutamide
-
10:09
reducing side effects of hormone therapy for prostate cancer | prostate cancer staging guide
-
7:00
comparing the second generation hormone therapies | ask a prostate expert, mark scholz, md
-
4:35
acebran 100 mg capsule uses & side effects in hindi | ऐसब्रान कैप्सूल
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
0:44
dr. wise on the fda approval of apalutamide in non-metastatic crpc
-
4:53
apalutamide: a next-gen agent for nonmetastatic crpc
-
2:28
dr. saad on recent updates in active surveillance in prostate cancer
-
5:20
apalutamide in treating nonmetastatic crpc
-
1:10
dr. gomella on the fda approval of apalutamide for nonmetastatic crpc
-
0:57
dr. morris on os data with apalutamide in prostate cancer
-
1:50
dr. kohli on the use of enzalutamide and apalutamide in mhspc
-
6:42
titan trial
-
1:46
dr. agarwal on the qol with apalutamide in metastatic castration-sensitive prostate cancer
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
1:28
apalutamide plus adt leads to survival benefit in mcspc